<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/31BAAEA1-1BCB-4D42-B1B3-4FC2539E6F43"><gtr:id>31BAAEA1-1BCB-4D42-B1B3-4FC2539E6F43</gtr:id><gtr:name>Public Health England</gtr:name><gtr:department>Microbiology Services (MS) Colindale</gtr:department><gtr:address><gtr:line1>Porton Down</gtr:line1><gtr:line4>Salisbury</gtr:line4><gtr:line5>Wiltshire</gtr:line5><gtr:postCode>SP4 0JG</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/31BAAEA1-1BCB-4D42-B1B3-4FC2539E6F43"><gtr:id>31BAAEA1-1BCB-4D42-B1B3-4FC2539E6F43</gtr:id><gtr:name>Public Health England</gtr:name><gtr:address><gtr:line1>Porton Down</gtr:line1><gtr:line4>Salisbury</gtr:line4><gtr:line5>Wiltshire</gtr:line5><gtr:postCode>SP4 0JG</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/3F38FC7E-CA1A-455E-A72D-1438369CFA31"><gtr:id>3F38FC7E-CA1A-455E-A72D-1438369CFA31</gtr:id><gtr:firstName>Kate</gtr:firstName><gtr:surname>Soldan</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/3B037B10-055C-4363-9A90-E65A84CD482B"><gtr:id>3B037B10-055C-4363-9A90-E65A84CD482B</gtr:id><gtr:firstName>Elizabeth</gtr:firstName><gtr:surname>Miller</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/222182CE-A89D-4AB0-895C-AC88C01D36C2"><gtr:id>222182CE-A89D-4AB0-895C-AC88C01D36C2</gtr:id><gtr:firstName>Morag</gtr:firstName><gtr:surname>Ferguson</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/8401830B-6167-422E-B12A-03843B1CC441"><gtr:id>8401830B-6167-422E-B12A-03843B1CC441</gtr:id><gtr:firstName>John</gtr:firstName><gtr:surname>Parry</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/08D72DE7-99FF-4381-BDA1-752616D3C540"><gtr:id>08D72DE7-99FF-4381-BDA1-752616D3C540</gtr:id><gtr:firstName>Stephen</gtr:firstName><gtr:surname>Inglis</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/92F4AEEF-B7EA-430E-ACBB-6FBED9F8A75B"><gtr:id>92F4AEEF-B7EA-430E-ACBB-6FBED9F8A75B</gtr:id><gtr:firstName>Mark</gtr:firstName><gtr:surname>Jit</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/EC790139-A367-425A-83F5-2CB1883E08F5"><gtr:id>EC790139-A367-425A-83F5-2CB1883E08F5</gtr:id><gtr:firstName>Simon</gtr:firstName><gtr:surname>Beddows</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/FCB4026A-52F0-4EC8-BF48-C7917278AEAB"><gtr:id>FCB4026A-52F0-4EC8-BF48-C7917278AEAB</gtr:id><gtr:firstName>Dianna</gtr:firstName><gtr:surname>Wilkinson</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0701217"><gtr:id>FFBD2C65-0BBD-4A13-8649-C002CF0D6C6C</gtr:id><gtr:title>Immune responses to HPV vaccines: Understanding antigenic relationships between genotypes to inform control strategies</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0701217</gtr:grantReference><gtr:abstractText>Cervical screening (the ?smear test?) helps prevent cervical cancer by finding early signs of abnormalities that can be dealt with before they progress to cancer. Another way to prevent disease is to block infection by the human papillomavirus (HPV) types that can lead, usually after many years, to the development of cervical cancer. Vaccines are available that protect women from two of the most common types of HPV which should lead to a reduction of about 70% of cervical cancers. However, as there are other HPV types that also cause cervical cancer it will be necessary to maintain the cervical cancer screening programme, a significant recurrent investment by the NHS, to protect the UK population from this devastating disease. In this study, we will examine the antibodies produced by animals and humans in response to HPV immunisation and work out how effective the vaccines are against other types of HPV. This information will be used to map the relationships between HPV types and help predict what will happen to each HPV type when the population is vaccinated. We will also use this model to describe potential gaps in protection that can be filled by the next generation of vaccines. This information may also help to target limited NHS resources to those individuals who may not be sufficiently protected by vaccination.</gtr:abstractText><gtr:technicalSummary>The recent development of vaccines against the Human Papillomavirus (HPV) represents one of the most significant advances in human vaccination for many years. Two vaccines targeted against the principal causes of cervical cancer (HPV genotypes 16 and 18) have now been licensed and are being introduced in several countries following highly successful clinical trials. The UK Department of Health announced recently its agreement, in principle, with Joint Committee on Vaccination and Immunisation advice to introduce an HPV vaccination programme involving routine vaccination of girls around 12-13 years of age subject to favourable peer reviewed cost-effectiveness analyses. These vaccines promise to reduce dramatically the considerable global burden of cervical cancer. However, as humoral immunity to HPV is predominantly type-specific and the vaccine-incorporated oncogenic genotypes account for only ~70% of cervical cancers, the burden of disease due to other HPV types is likely to remain significant. While the diversity between HPV types is well recognised at the genetic level it is still unclear how, and to what extent, these differences impact on functionally-relevant antigenic relatedness. While monitoring incident type-specific HPV infection at a population level once routine HPV vaccination becomes implemented will improve predictions of cross-protection, true vaccine-induced cross-reactivity can only be determined empirically. Our goal is to build a comprehensive relational antigenic map of the HPV major capsid protein, using data generated from functional (neutralisation) assays, by making use of large panels of mono- and poly-specific sera. Serum samples will be obtained from human vaccines (N~400) and from animals (mice, N~100 and rabbits, N~20). Once the degree of antigenic relatedness of distinct HPV genotypes has been mapped, we will estimate the expected cross-protection of vaccines at a population level. We will also develop, as an integral part of the project, standards and reference materials, and assay protocols to be made available internationally to support HPV vaccine research. This work will contribute to priority setting for subsequent generations of HPV vaccines and to assessing the potential impact of future vaccination and cervical screening strategies.</gtr:technicalSummary><gtr:fund><gtr:end>2011-12-31</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2008-07-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>596909</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>10000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>N/A - registration of staff scientist for PhD studies</gtr:description><gtr:end>2014-03-02</gtr:end><gtr:fundingOrg>Public Health England (formerly: Health Protection Agency)</gtr:fundingOrg><gtr:fundingRef>N/A</gtr:fundingRef><gtr:id>E00A0D3C-F5DA-47DC-81C1-8D733B23EBE0</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2010-03-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Codon-optimized expression clones for the L1 and L2 genes of human papillomavirus 35, 39 and 59 to enable generation of replication-incompetent pseudoviruses</gtr:description><gtr:id>CC18BFF2-718D-449B-90D8-91F757BAE52D</gtr:id><gtr:impact>Clone details deposited at the National Cancer Institute, Bethesda, USA (http://home.ccr.cancer.gov/lco/default.asp) and have already been made available to several international research groups. Deposited at AddGene repository (http://www.addgene.org/Simon_Beddows)</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>HPV Pseudovirus Clones</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:url>http://home.ccr.cancer.gov/lco/default.asp</gtr:url><gtr:yearFirstProvided>2010</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Pools of plasma from HPV negative and HPV vaccine antibody positive individuals for use in post-vaccine surveillance and research</gtr:description><gtr:id>0F61906B-F5E5-4DE8-9F6A-C8FD8EEB9658</gtr:id><gtr:impact>Human papillomavirus antibody reference reagents for use in postvaccination surveillance serology. Bissett SL, Wilkinson D, Tettmar KI, Jones N, Stanford E, Panicker G, Faust H, Borrow R, Soldan K, Unger ER, Dillner J, Minor P, Beddows S. Clin Vaccine Immunol. 2012 Mar;19(3):449-51. Epub 2012 Jan 25. PMID:22278326</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>HPV Plasma Pools</gtr:title><gtr:type>Antibody</gtr:type><gtr:url>http://europepmc.org/abstract/MED/22278326</gtr:url><gtr:yearFirstProvided>2012</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7C5DAE6F-9ABB-474B-9C43-9BC558A2ABEE"><gtr:id>7C5DAE6F-9ABB-474B-9C43-9BC558A2ABEE</gtr:id><gtr:title>Neutralization of non-vaccine human papillomavirus pseudoviruses from the A7 and A9 species groups by bivalent HPV vaccine sera.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/7f3d5122d276174a0458f35dddbe6756"><gtr:id>7f3d5122d276174a0458f35dddbe6756</gtr:id><gtr:otherNames>Draper E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/12035D0E-DF99-44E5-A3F6-41D8E69F0F97"><gtr:id>12035D0E-DF99-44E5-A3F6-41D8E69F0F97</gtr:id><gtr:title>Pre-clinical immunogenicity of human papillomavirus alpha-7 and alpha-9 major capsid proteins.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c92834068446e7f328f7087be4187cee"><gtr:id>c92834068446e7f328f7087be4187cee</gtr:id><gtr:otherNames>Bissett SL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/CB7597E6-7010-4F5B-9E0D-9951914BDF14"><gtr:id>CB7597E6-7010-4F5B-9E0D-9951914BDF14</gtr:id><gtr:title>A randomized, observer-blinded immunogenicity trial of Cervarix(&amp;reg;) and Gardasil(&amp;reg;) Human Papillomavirus vaccines in 12-15 year old girls.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/7f3d5122d276174a0458f35dddbe6756"><gtr:id>7f3d5122d276174a0458f35dddbe6756</gtr:id><gtr:otherNames>Draper E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/43A036F9-2A6C-4A4B-8637-B3CA0116402B"><gtr:id>43A036F9-2A6C-4A4B-8637-B3CA0116402B</gtr:id><gtr:title>Human papillomavirus antibody reference reagents for use in postvaccination surveillance serology.</gtr:title><gtr:parentPublicationTitle>Clinical and vaccine immunology : CVI</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c92834068446e7f328f7087be4187cee"><gtr:id>c92834068446e7f328f7087be4187cee</gtr:id><gtr:otherNames>Bissett SL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1556-679X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B20F52A9-4D4B-43C4-A229-89242C9971AE"><gtr:id>B20F52A9-4D4B-43C4-A229-89242C9971AE</gtr:id><gtr:title>Relationship between Humoral Immune Responses against HPV16, HPV18, HPV31 and HPV45 in 12-15 Year Old Girls Receiving Cervarix&amp;reg; or Gardasil&amp;reg; Vaccine.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ba4e15d9fa3fb579891bbc4b778ae2e7"><gtr:id>ba4e15d9fa3fb579891bbc4b778ae2e7</gtr:id><gtr:otherNames>Godi A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E4B44765-867F-468F-9DED-77EF73FF329F"><gtr:id>E4B44765-867F-468F-9DED-77EF73FF329F</gtr:id><gtr:title>Systemic and mucosal immune responses to sublingual or intramuscular human papilloma virus antigens in healthy female volunteers.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4e48c989020eaccb90eb3306ab4cbfd2"><gtr:id>4e48c989020eaccb90eb3306ab4cbfd2</gtr:id><gtr:otherNames>Huo Z</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/255D5D13-1F8C-4062-A169-B12E0C438D88"><gtr:id>255D5D13-1F8C-4062-A169-B12E0C438D88</gtr:id><gtr:title>Cross-neutralizing antibodies elicited by the Cervarix&amp;reg; human papillomavirus vaccine display a range of Alpha-9 inter-type specificities.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c92834068446e7f328f7087be4187cee"><gtr:id>c92834068446e7f328f7087be4187cee</gtr:id><gtr:otherNames>Bissett SL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/CB903DE4-4A62-45B4-82AE-9CBB413A1295"><gtr:id>CB903DE4-4A62-45B4-82AE-9CBB413A1295</gtr:id><gtr:title>Relationship between Humoral Immune Responses against HPV16, HPV18, HPV31 and HPV45 in 12-15 Year Old Girls Receiving Cervarix&amp;reg; or Gardasil&amp;reg; Vaccine.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ba4e15d9fa3fb579891bbc4b778ae2e7"><gtr:id>ba4e15d9fa3fb579891bbc4b778ae2e7</gtr:id><gtr:otherNames>Godi A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0701217</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>D8F3A27D-084A-40BB-A046-087DACE23410</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>3.4  Vaccines</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>